The prevalence of quadriceps weakness in COPD and the relationship with disease severity.
The prevalence of quadriceps weakness in COPD and the relationship with disease severity.
复制标题
DOI：
10.1183/09031936.00104909
复制
发表时间：
2010-07
期刊：
影响因子：
--
通讯作者：
Wouters EF
中科院分区：
文献类型：
--
作者：
Seymour JM;Spruit MA;Hopkinson NS;Natanek SA;Man WD;Jackson A;Gosker HR;Schols AM;Moxham J;Polkey MI;Wouters EF
股四头肌力量与慢性阻塞性肺疾病（COPD）患者的运动能力和预后有关。我们希望量化COPD患者股四头肌无力的患病率，并假设其不限于严重气流阻塞或呼吸困难的患者。根据212名健康受试者的测量结果，使用回归方程（包括年龄、性别、身高和无脂肪质量）计算预测的股四头肌力量。在从英国（n=240）和荷兰（n=351）招募的两个稳定期COPD门诊患者队列中，虚弱患病率（定义为观察值低于预测值1.645标准化残差）与GOLD分期和医学研究理事会（MRC）呼吸困难评分相关。32%的英国和33%的荷兰COPD患者有股四头肌无力。GOLD 1级和2级或MRC呼吸困难评分为1或2的患者中，有相当比例的患者存在股四头肌无力（分别为28%和26%）。这些值在GOLD 4期中上升至38%，在MRC评分为4或5的患者中上升至43%。四头肌无力在三分之一的COPD患者参加医院呼吸门诊服务。股四头肌无力存在于没有严重气流阻塞或呼吸困难的情况下。
Quadriceps strength relates to exercise capacity and prognosis in chronic obstructive pulmonary disease (COPD). We wished to quantify the prevalence of quadriceps weakness in COPD, and hypothesised that it would not be restricted to patients with severe airflow obstruction or dyspnoea. Predicted quadriceps strength was calculated using a regression equation (incorporating age, gender, height and fat-free mass), based on measurements from 212 healthy subjects. The prevalence of weakness (defined as observed values 1.645 standardised residuals below predicted) was related to GOLD stage and Medical Research Council (MRC) dyspnoea score in two cohorts of stable COPD outpatients recruited from the United Kingdom (n=240) and the Netherlands (n=351). 32% and 33% of UK and Dutch COPD patients had quadriceps weakness. A significant proportion of patients in GOLD stages 1 and 2, or with an MRC dyspnoea score of 1 or 2, had quadriceps weakness (28% and 26% respectively). These values rose to 38% in GOLD stage 4, and 43% in patients with an MRC Score of 4 or 5. Quadriceps weakness was demonstrable in one-third of COPD patients attending hospital respiratory outpatient services. Quadriceps weakness exists in the absence of severe airflow obstruction or breathlessness.
登录
查看更多内容
影响因子：
9.6
作者：
Mador, MJ;Bozkanat, E;Kufel, TJ
通讯作者：
Kufel, TJ
DOI：
10.1042/cs0520283
发表时间：
1977-01-01
期刊：
CLINICAL SCIENCE AND MOLECULAR MEDICINE
影响因子：
--
作者：
EDWARDS, RHT;YOUNG, A;JONES, DA
通讯作者：
JONES, DA
影响因子：
105.7
作者：
FLETCHER, CM;ELMES, PC;WOOD, CH
通讯作者：
WOOD, CH
影响因子：
24.3
作者：
Hopkinson, NS;Man, WDC;Polkey, MI
通讯作者：
Polkey, MI
影响因子：
24.3
作者：
Miller, MR;Hankinson, J;Wanger, J
通讯作者：
Wanger, J